Vaping Expected to Increase COPD Health and Economic Burden by 2050
New ResMed-supported research presented at ERS 2024 projects future Chronic Obstructive Pulmonary Disease (COPD) burden in Western Europe, accounting for increased air pollution, tobacco smoking, and vaping, with Non-Invasive Ventilation (NIV) enhancing survival rates.
- 88.7 million new COPD hospitalizations projected across Western Europe between 2019 - 2050
- Vaping projected to incur almost €30 billion additional direct and indirect costs by 2050
- €4.9 trillion projected cumulative cost to support COPD lung conditions by 2050
- 16% projected reduction in risk of death after a severe exacerbation for COPD patients using home NIV support
SAN DIEGO and VIENNA, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ResMed presented 18 supported studies at ERS 2024, including research that projects vaping, smoking, and air pollution will substantially increase the economic and public health burden of COPD in Western Europe. Annual direct and indirect costs are projected to reach over €170 billion by 2050, costing Western European economies over €4.9 trillion cumulatively by 2050. Vaping alone is forecast to require an additional €3.78 billion annually to support its impact on medical care and societal costs.
COPD poses a significant health and economic burden, further exacerbated by environmental and behavioral changes such as air pollution and vaping. Previous modeling work has focused on quantifying the burden of COPD across North America, accounting for tobacco smoking and air pollution1. The ResMed-supported research aimed to extend this US modeling by also accounting for the effects of vaping on the COPD burden in Western Europe2.
The results of this pertinent research were presented at ERS 2024 by Elroy Boers, PhD, Lead Health Research Scientist, ResMed. The model projected that, in addition to smoking and air pollution, vaping is going to have a notable economic and health impact on the burden of COPD into 2050, both cumulatively and annually.
2050 outcomes describing the relative increase associated with vaping (vs. the scenario without vaping) were concluded to be:
- Direct costs are projected to relatively increase by 0.5% (cumulative) and 2.1% (annual) – representing a cumulative increase of €10 billion.
- Indirect costs are projected to relatively increase by 0.7% (cumulative) and 2.3% (annual) – representing a cumulative increase of €20 billion.
- The number of exacerbations is estimated to relatively increase by 0.3% or 1.6 million (cumulative) and 1.8% (annual)
- The number of hospitalizations is projected to increase by 0.2% or 190,000 (cumulative) and 3.3% (annual).
“To avoid escalating costs to public finances, additional strain on health services, and reduce loss of life from COPD, much greater action is required. Public health and advocacy efforts targeting known risk factors such as smoking, vaping, and ambient and household air pollution may be critical to prevent this anticipated burden,” said ResMed Chief Medical Officer Carlos M. Nunez, M.D.
In a separate ResMed-supported study presented by Professor Jean-Louis Pépin, Grenoble Alpes University, France, the role of home non-invasive Ventilation (NIV) support in managing COPD was explored. The study found that continued use of home NIV significantly reduces risk of death from COPD flare-ups (exacerbations), with a 16% reduction in mortality risk following severe exacerbations and a 12% reduction for those without exacerbations. The study involved nearly 50,000 adults with COPD who were treated via home NIV. The multistate model analysis estimated the impact of NIV continuation versus cessation on transitions between three different disease states (without severe exacerbation, severe exacerbation, and death).
“The positive impact of home NIV in reducing risk of death offers some comfort for those millions of people already suffering from COPD and those who will suffer in years to come. However, proactive work now on the part of potential patients and their loved ones to learn and recognize symptoms early, as well as preventative steps to reduce risk factors, will go a long way toward positively impacting hundreds of millions of lives worldwide,” Nunez continued. “Education and meaningful action are essential to curbing the number of people impacted by COPD and life-threatening events caused by these conditions.”
Complete list of ResMed-supported studies presented at ERS 2024:
- The modified Baveno classification for obstructive sleep apnoea management
- Impact of home NIV on severe exacerbations and survival in COPD: a French nationwide cohort study using multistate models
- Light, latitude and Epworth Sleepiness Scale in the European Sleep Apnea database - a daring proposal
- The economic and health burden of COPD in Western Europe through 2050: a scenario analysis based on two large data sources
- Role of Partnership in PAP Therapy Adoption in Obstructive Sleep Apnoea
- A negative effect by ATC N-class treatment in OSA patients with concomitant psychiatric disease: an ESADA cohort study.
- Association of sleep-related hypoxia with survival in patients with non-small cell lung cancer – the NEOSAS-GFPC study group
- Adaptive servo-ventilation (ASV) in patients with central or complex sleep apnea and associated cardiovascular comorbidities: the READ-ASV registry
- Effect of adaptive servo-ventilation on cardiac repolarization in patients with myocardial infarction and sleep-disordered breathing
- Effect of non-respiratory arousals on residual sleepiness in CPAP-treated OSA patients
- The association between behavioural clusters and short-term PAP usage in OSA
- PAP use in OSA patients with and without insomnia
- Usage of adaptive servo-ventilation (ASV): results from the READ-ASV registry
- A scenario-based modelling study to project the future burden of COPD in Western Europe accounting for air pollution, tobacco smoking, and e-cigarette vaping
- Obstructive Sleep Apnoea and C-reactive protein levels: Data from the ESADA
- Preserved ratio impaired spirometry and OSA may contribute to cardio-metabolic complications: evidence from the ESADA cohort
- Comparisons of cardiovascular risk scores in patients with obstructive sleep apnea - the European Sleep Apnea Database (ESADA)
- Effect of CPAP on circulating levels of MPO and MMP-9 in adults with coronary artery disease and obstructive sleep apnoea: the RICCADSA randomized controlled trial
About ResMed
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.
For Media
Emily Yandle
ResMedUK@teamlewis.com
Julia Moser
news@resmed.com
1 E. Boers, A. Allen, A. Benjafield, M. Barrett, and A. Malhotra. The Economic and Health Burden of COPD in North America: Forecasting Through 2050 (abstract). Am J Respir Crit Care Med2023;207:A3593.
2 E. Boers, A. Allen, A. Benjafield, L.E. Crotty Alexander, A. Malhotra and M. Barrett. A scenario-based modeling study to project the future burden of COPD in Western Europe accounting for air pollution, tobacco smoking, and e-cigarette vaping. (abstract). ERS 2024.
- 贵州融州华企业管理有限公司:助力企业财税管理,专业定制化服务保驾护航
- 特别报道:王无极受聘为中尼文化交流使者
- 杭州市电子商务协会绿色电商专委会成立 愿景未来任执行主任单位
- Constellation Brands Appoints Sam Glaetzer to Lead Company’s Wine & Spirits Division
- 【中科时代产品战略发布会与可计算制造高峰论坛】于中国·深圳成功召开!
- 全球最著名的滚石摇滚乐队选择雷霆岭自然剧场作为北美最后一场演出的场地
- 龙顺国际物流受邀参加广东3.15晚会丨共筑诚信物流新篇章
- 药易购2023财年净利同比增加41.69% ,营收突破44亿元
- 中国宣传网:携手共进,开创宣传新时代
- 中信银行太原迎西支行:服务无小事 上门暖人心
- 吴中集团落户苏州工业园区,助力服务行业新质生动力
- 别再空谈勤洗手!对抗诺如病毒需要强有力防护
- 成都市鑫汇泰达企业管理有限公司:打造卓越企业形象,提升竞争力
- 中信银行发布《2023年度环境信息披露(TCFD)报告》
- 尼尔森IQ联合饿了么发布《2024即时零售冰品酒饮消费洞察》
- 贝康医疗(2170.HK):销售收入增长46%,毛利72%,国际化布局初见成效
- 与一般的宠物托运公司不同的是,这家公司不仅限于
- 平安养老险新疆分公司:积极开展2024年“78奋力前行”活动
- 故园情思,丹青境幽——向极鄢国画作品的审美情怀和形式特征
- Philips delivers strong order intake growth in the second quarter, margin improvement and sales grow
- Pluxee delivers strong performance in the First Half and raises Fiscal 2024 Organic revenue growth a
- 斑斓多彩的活动、精神丰盈的居民,描绘出那香海社区的幸福画卷
- 碧丽花岗岩石漆携手IPTV重磅亮相央视春节联欢晚会,开拓品牌传播新势能!
- 岁寒情暖,平安廖河——平安养老险安徽分公司开展帮扶走访慰问
- 《特簇之画》开机仪式:点燃希望之光
- 中天医疗颈动脉支架进入创新绿色通道,开启CAS解决方案新篇
- Mohawk Industries Reports Q2 Results
- Instagram私信采集软件,ins精准私信工具,ig快速引流神器/ins协议号批量出售
- 重庆手绘浮雕壁画专业团队公司【美佳彩绘】
- Myrobalan Therapeutics 任命 Grant Bogle 为董事会成员
推荐
- 新增供热能力3200万平方米 新疆最大热电联产项目开工 昨天(26日),新疆最大的热电联产项目—&md 资讯
- 海南大学生返校机票贵 有什么好的解决办法吗? 近日,有网友在“人民网领导留言板&rdqu 资讯
- 产业数字化 为何需要一朵实体云? 改革开放前,国内供应链主要依靠指标拉动,其逻 资讯
- 中国减排方案比西方更有优势 如今,人为造成的全球变暖是每个人都关注的问 资讯
- 抖音直播“新红人”进攻本地生活领域 不难看出,抖音本地生活正借由直播向本地生活 资讯
- 一个“江浙沪人家的孩子已经不卷学习了”的新闻引发议论纷纷 星标★ 来源:桌子的生活观(ID:zzdshg) 没 资讯
- 大家一起关注新疆乌什7.1级地震救援见闻 看到热气腾腾的抓饭马上就要出锅、村里大家 资讯
- 周星驰新片《少林女足》在台湾省举办海选,吸引了不少素人和足球爱好者前来参加 周星驰新片《少林女足》在台湾省举办海选,吸 资讯
- 国足13次出战亚洲杯首次小组赛0进球 北京时间1月23日消息,2023亚洲杯小组 资讯
- 中央气象台连发四则气象灾害预警 暴雪橙色预警+冰冻橙色预警+大雾黄色预警+ 资讯